Back to Search Start Over

ERS Genomics & AlgenScribe enter into CRISPR/Cas9 licensing agreement

Source :
PharmaBiz. September 6, 2023
Publication Year :
2023

Abstract

ERS Genomics Limited (ERS), a biotechnology company, has announce a new license agreement with AlgenScribe SAS (AlgenScribe). This is a non-exclusive licensing agreement granting AlgenScribe access to the ERS CRISPR/Cas9 [...]

Details

Language :
English
Database :
Gale General OneFile
Journal :
PharmaBiz
Publication Type :
Periodical
Accession number :
edsgcl.763521859